Patents by Inventor Michael E. Garst

Michael E. Garst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 8993780
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 31, 2015
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • DIPHENYL UREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS
    Publication number: 20150080466
    Abstract: The present invention relates to diphenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 19, 2015
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • CYCLOSPORIN ANALOGS
    Publication number: 20150065433
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Applicant: ALLERGAN, INC.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Process for the synthesis of substituted gamma lactams
    Patent number: 8962863
    Abstract: The present invention provides synthetic processes for the preparation of a variety of well-defined substituted gamma lactams. The compounds that can be prepared by the process of the invention are useful for treating a variety of conditions. In some embodiments of the invention, the compounds are useful for treating ocular disorders, such as, for example, glaucoma, lowering of elevated intraocular pressure, and the like. In other embodiments, the compounds are useful for treating irritable bowel disease. In further embodiments, the compounds are useful in promoting hair growth. In still further embodiments, the compounds are useful in promoting wound healing, scar reduction, and the like.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: February 24, 2015
    Assignee: Allergan, Inc.
    Inventors: Danny T. Dinh, Michael E. Garst, David W. Old, Elizabeth T. Syage, Boris Gorin, Christopher M. Lanthier, Jan Oudenes
  • DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR MODULATORS
    Publication number: 20150025021
    Abstract: The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 22, 2015
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT
    Publication number: 20150011591
    Abstract: The present invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.
    Type: Application
    Filed: September 24, 2014
    Publication date: January 8, 2015
    Inventors: George R. Ehring, Ellen Chao, Herman Ng, Hau Ton, Jia Chian Li, Joseph S. Adorante, Michael E. Garst, Howard B. Rind, Mark R. Hansen, Alfred Arthur Avey, JR., Lloyd Jay Dolby, Shervin Esfandiari, Vivian R. MacKenzie, Jeremiah Andrew Marsden, David Charles Muchmore
  • Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators
    Patent number: 8927544
    Abstract: The present invention relates to benzofuran-2-sulfonamide derivatives with the following formula: or pharmaceutically acceptable salts thereof. The derivatives are useful as modulators of chemokine receptors.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: January 6, 2015
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • ESTER DERIVATIVES OF BIMATOPROST COMPOSITIONS AND METHODS
    Publication number: 20150005377
    Abstract: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 1, 2015
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd S. Gac, Robert M. Burk, Michael E. Garst
  • SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20140378492
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Inventors: HAIQING YUAN, RICHARD L. BEARD, MICHAEL E. GARST, JOHN E. DONELLO, XIAOXIA LIU, VEENA VISWANATH
  • N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
    Publication number: 20140329852
    Abstract: The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: July 15, 2014
    Publication date: November 6, 2014
    Inventors: Liming Wang, Mohammed I. Dibas, Michael E. Garst, KEN CHOW, Santosh C. Sinha
  • BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20140329813
    Abstract: The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, Xiaoxia Liu, John E. Donello, Veena Viswanath
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 8877804
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: November 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, John E. Donello, Xiaoxia Liu, Veena Viswanath
  • Ester derivatives of bimatoprost compositions and methods
    Patent number: 8865766
    Abstract: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: October 21, 2014
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd Gac, Robert M. Burk, Michael E. Garst
  • Ester pro-drugs of [3-(1-(1H-imidazol-4-YL)ethyl)-2-methylphenyl] methanol for treating retinal diseases
    Patent number: 8853251
    Abstract: The present invention relates to method of treating retinal diseases in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: October 7, 2014
    Assignee: Allergan, Inc.
    Inventors: Mohammed I. Dibas, Daniel W. Gil, Ken Chow, Liming Wang, Michael E. Garst, John E. Donello
  • Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 8846760
    Abstract: The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: September 30, 2014
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Vidyasagar Vuligonda, John E. Donello, Veena Viswanath, Michael E. Garst, Thong Vu
  • PYRIDINYL AND PYRIMIDINYL SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20140275132
    Abstract: The present invention relates to novel pyridine or pyrimidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with chemokine receptor modulation.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Allergan, Inc.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath, Michael E. Garst, Haiqing Yuan, Xiaoxia Liu
  • Steroid conjugates
    Publication number: 20140256696
    Abstract: The present invention describes steroid conjugates. These single drug entities are formed by connecting two or more steroids via a linker. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual steroid drugs.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS
    Publication number: 20140256660
    Abstract: The present invention describes novel single drug entities, formed by the linkage of an antibiotic with a steroidal drug via a linker. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • ANTIBIOTIC CONJUGATES DIRECTLY LINKED WITH STEROID DRUGS
    Publication number: 20140256612
    Abstract: The present invention describes novel single drug entities, formed by direct linkage of an antibiotic to a steroidal drug. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. The antibiotic is coupled directly to the steroid drug.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
    Publication number: 20140256666
    Abstract: The present invention describes single drug entities, formed by connecting an antibiotic moiety via a linker with a non-steroidal anti-inflammatory drug (NSAID) moiety. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual antibiotic and NSAID drug.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT